{
    "id": "correct_subsidiary_00046_2",
    "rank": 20,
    "data": {
        "url": "https://www.epa.gov/npdes-permits/npdes-pretreatment-discharge-requirements-gsk-hamilton-pharmaceuticals-montana",
        "read_more_link": "",
        "language": "en",
        "title": "NPDES Pretreatment Discharge Requirements for GSK-Hamilton Pharmaceuticals in Montana",
        "top_image": "https://www.epa.gov/sites/all/themes/epa/img/epa-standard-og.jpg",
        "meta_img": "https://www.epa.gov/sites/all/themes/epa/img/epa-standard-og.jpg",
        "images": [
            "https://www.epa.gov/themes/epa_theme/images/us_flag_small.png",
            "https://www.epa.gov/themes/epa_theme/images/icon-dot-gov.svg",
            "https://www.epa.gov/themes/epa_theme/images/icon-https.svg",
            "https://www.epa.gov/themes/epa_theme/images/epa-seal.svg"
        ],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            ""
        ],
        "tags": null,
        "authors": [
            "US EPA"
        ],
        "publish_date": "2020-12-23T17:51:27-05:00",
        "summary": "",
        "meta_description": "Under NPDES control mechanism MT-PF00103, GSK-Hamilton is authorized to discharge wastewater to the City of Hamilton, Montana, publicly operated treatment works (POTW).",
        "meta_lang": "en",
        "meta_favicon": "/themes/epa_theme/images/favicon.ico",
        "meta_site_name": "US EPA",
        "canonical_link": "https://www.epa.gov/npdes-permits/npdes-pretreatment-discharge-requirements-gsk-hamilton-pharmaceuticals-montana",
        "text": "The GSK-Hamilton facility is a campus with buildings that support pharmaceutical manufacturing of MPL and QS-21 adjuvants. These adjuvants are shipped offsite to other GSK locations for vaccine formulation. The GSK-Hamilton facility is owned by Corixa Corporation dba GlaxoSmithKline Vaccines. GSK is authorized under the Pretreatment Notice of Discharge Requirements, MT-PF00103 to discharge the wastewaters generated from these manufacturing processes and treated to the City of Hamiltonâ€™s publicly owned treatment works (POTW). Authorization for discharge is limited to only those outfalls specifically listed in the notice of discharge requirements.\n\nGSK-Hamilton Pretreatment Notification Letter MTPF00103 (pdf)\n\nGSK Hamilton Discharge Requirements MTPF00103 (pdf)\n\nGSK Hamilton Fact Sheet MTPF00103 (pdf)"
    }
}